These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection. Chan JG; Tyne AS; Pang A; Chan HK; Young PM; Britton WJ; Duke CC; Traini D Pharm Res; 2014 May; 31(5):1239-53. PubMed ID: 24242939 [TBL] [Abstract][Full Text] [Related]
8. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin. Pai RV; Jain RR; Bannalikar AS; Menon MD J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162 [TBL] [Abstract][Full Text] [Related]
9. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Zhang T; Zhang M; Rosenthal IM; Grosset JH; Nuermberger EL Am J Respir Crit Care Med; 2009 Dec; 180(11):1151-7. PubMed ID: 19729664 [TBL] [Abstract][Full Text] [Related]
10. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. Chan JG; Chan HK; Prestidge CA; Denman JA; Young PM; Traini D Eur J Pharm Biopharm; 2013 Feb; 83(2):285-92. PubMed ID: 22982733 [TBL] [Abstract][Full Text] [Related]
11. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis. Rawal T; Kremer L; Halloum I; Butani S J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480 [TBL] [Abstract][Full Text] [Related]
12. A study on polymorphic forms of rifampicin for inhaled high dose delivery in tuberculosis treatment. Khadka P; Hill PC; Zhang B; Katare R; Dummer J; Das SC Int J Pharm; 2020 Sep; 587():119602. PubMed ID: 32663580 [TBL] [Abstract][Full Text] [Related]
13. Colistin powders with high aerosolisation efficiency for respiratory infection: preparation and in vitro evaluation. Zhou QT; Morton DA; Yu HH; Jacob J; Wang J; Li J; Chan HK J Pharm Sci; 2013 Oct; 102(10):3736-47. PubMed ID: 23904207 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of highly branched cyclic dextrin in inhalable particles of combined antibiotics for the pulmonary delivery of anti-tuberculosis drugs. Kadota K; Senda A; Tagishi H; Ayorinde JO; Tozuka Y Int J Pharm; 2017 Jan; 517(1-2):8-18. PubMed ID: 27913241 [TBL] [Abstract][Full Text] [Related]
15. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182 [TBL] [Abstract][Full Text] [Related]
16. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? Alfarisi O; Alghamdi WA; Al-Shaer MH; Dooley KE; Peloquin CA Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1027-1036. PubMed ID: 28803492 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Inhaled Rifampicin Porous Particles for Tuberculosis Treatment: Insight into Rifampicin Absorption from the Lungs of Guinea Pigs. Garcia Contreras L; Sung J; Ibrahim M; Elbert K; Edwards D; Hickey A Mol Pharm; 2015 Aug; 12(8):2642-50. PubMed ID: 25942002 [TBL] [Abstract][Full Text] [Related]
18. A new respirable form of rifampicin. Son YJ; McConville JT Eur J Pharm Biopharm; 2011 Aug; 78(3):366-76. PubMed ID: 21324356 [TBL] [Abstract][Full Text] [Related]
19. Preparation of sustained release rifampicin microparticles for inhalation. Son YJ; McConville JT J Pharm Pharmacol; 2012 Sep; 64(9):1291-302. PubMed ID: 22881441 [TBL] [Abstract][Full Text] [Related]
20. Monitoring safety of liposomes containing rifampicin on respiratory cell lines and in vitro efficacy against Mycobacterium bovis in alveolar macrophages. Changsan N; Nilkaeo A; Pungrassami P; Srichana T J Drug Target; 2009 Dec; 17(10):751-62. PubMed ID: 19863196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]